DSM Signs Supply Pacts with Opthea and Sanquin - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

DSM Signs Supply Pacts with Opthea and Sanquin



Untitled Document

DSM Pharmaceutical has developed supply pacts with Opthea and Sanquin. The agreement with Opthea of Melbourne, Australia covers process development and cGMP manufacture by DSM for Opthea's lead molecule, a soluble form of human VEGFR-3 that blocks the activity of both VEGF-C and VEGF-D, which promote blood and lymphatic vessel formation and are involved in the progression of eye diseases.

This project represents an agreement for process development at DSM Biologics' Groningen, the Netherlands, facility and manufacture at the company’s newly established cGMP facility in Brisbane, Australia. Opthea, a private 100% owned subsidiary of Circadian Technologies is developing its lead molecule OPT-302, previously known as VGX-300, initially for the treatment of "wet" (neovascular) age-related macular degeneration.

In other news, DSM has signed an agreement with the Sanquin Blood Supply Foundation for the commercial manufacture of a monoclonal antibody (mAb) used for the recovery and purification of coagulation factor IX from human blood. Collaboration between DSM Biologics, a business unit of DSM Pharmaceutical Products, and Sanquin will entail subsequent GMP manufacture of the antifactor IX mAb at DSM Biologics’ facilities in Groningen, the Netherlands.

DSM becomes a second supplier to Sanquin for a process intermediate that is used for the capture of human factor IX from blood plasma.

Source: DSM Pharmaceutical

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here